(Q53559996)

15 May 2018

review article

1 reference

title

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. (English)

1 reference

15 May 2018

1 reference

Lebwohl D

1

1 reference

15 May 2018

Canetta R

series ordinal

2

1 reference

15 May 2018

publication date

1 September 1998

1 reference

15 May 2018

European Journal of Cancer

published in

1 reference

15 May 2018

volume

34

1 reference

15 May 2018

issue

10

1 reference

15 May 2018

page(s)

1522-1534

1 reference

15 May 2018

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Fundamental studies with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant diseas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobu

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Preclinical studies identifying carboplatin as a viable cisplatin alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Preclinical antitumor and toxicologic profile of carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Carboplatin: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

A phase II trial of zeniplatin in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4- butanediamine-N,N1) platinum in patients with metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Toxicological and tumoricidal evaluations of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)platinum( II) monohydrate, in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Antitumor activity of l-OHP in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Preclinical antitumor activity of orally administered platinum (IV) complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

New platinum complexes in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase II study of iproplatin in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

A phase II study of CHIP in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

Carboplatin: the clinical spectrum to date

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2898%2900224-X

7 January 2021

10.1016/S0959-8049(98)00224-X

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018